Home › NDC Lookup › Ingredients › Aluminum Chlorohydrate › 78283-0003-01
🧴image loading
(from DailyMed)

Babaria Double Effect Deodorant and Antiperspirant Liquid Roll-On ALUMINUM CHLOROHYDRATE 200 mg/mL Emulsion, 50 mL — NDC 78283-003-01 (Billing 78283-0003-01)

by BERIOSKA SL · 50 mL in 1 BOTTLE

This is a package of 50 mL of Babaria Double Effect Deodorant and Antiperspirant Liquid Roll-On ALUMINUM CHLOROHYDRATE 200 mg/mL Emulsion from BERIOSKA SL, marketed since Mar 2024 and currently FDA-listed, this package's marketing is listed to end Jan 2030. It is this product's only package size.

NDC 78283-0003-01
🏷️ FDA NDC (as labeled) 78283-003-01 billing pads the product segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 78283-003-01 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
78283 labeler · 003 product · 01 package
Package marketed since
Mar 18, 2024
Package marketing ended
Jan 1, 2030
Sample package
No — commercial package
Barcode (UPC)
8410412018555
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 78283-003-01
Product NDC 78283-003
11-digit billing NDC 78283000301
UNII HPN8MZW13M
UPC 8410412018555
Application # M019
SPL Set ID dd46db72-bc7b-400f-b396-45a680539767
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-03-18
Marketing end 2030-01-01
Route TOPICAL
Dosage form EMULSION
Substance ALUMINUM CHLOROHYDRATE
Why two NDCs? The FDA registers this code as 78283-003-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 78283-0003-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

🧪 What is this product?

Babaria Double Effect Deodorant and Antiperspirant is a topical liquid roll-on emulsion containing aluminum chlorohydrate. This ingredient is commonly used in over-the-counter antiperspirant products to help reduce underarm perspiration by forming a plug in sweat ducts. This product is marketed as an OTC monograph drug, meaning it follows FDA's established safety and effectiveness rules for the antiperspirant category rather than being individually reviewed before marketing.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
78283-0003-01 You're viewing this Main listing 50 mL in 1 BOTTLE 2024-03-18 Jan 1, 2030 Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Babaria Invisible Deodorant and Antiperspirant Liquid Roll-On 200 mg/mL 78283-0004-01 BERIOSKA 50 ml — — FDA listed —
Babaria Cotton Fresh Deodorant and Antiperspirant Liquid Roll-On 200 mg/mL 78283-0002-01 BERIOSKA 50 ml — — FDA listed —
Babaria Aloe Fresh Deodorant and Antiperspirant Liquid Roll-On 200 mg/mL 78283-0001-01 BERIOSKA 50 ml — — FDA listed —
Babaria Oat Fresh Deodorant and Antiperspirant Liquid Roll-On 200 mg/mL 78283-0005-01 BERIOSKA 50 ml — — FDA listed —
Babaria Skin Natural Fresh Deodorant and Antiperspirant Liquid Roll-On 200 mg/mL 78283-0007-01 BERIOSKA 50 ml — — FDA listed —
Babaria Double Effect Deodorant and Antiperspirant Liquid Roll-On 200 mg/mLthis 78283-0003-01 BERIOSKA 50 ml — — FDA listed —
Babaria Olive Fresh Deodorant and Antiperspirant Liquid Roll-On 200 mg/mL 78283-0006-01 BERIOSKA 50 ml — — FDA listed —
Youth Dew Roll-On Antiperspirant Deodorant 200 mg/mL 11559-0001-01 ESTEE 75 ml — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
Mar 2024
📍
2026
Currently FDA-listed
2 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBERIOSKA SL
FDA applicationM019 (OTC MONOGRAPH DRUG)
Labeler code78283
First marketedMar 2024
Product typeHuman Otc Drug
Portfolio7 products on file

More NDCs from BERIOSKA SL labeler code 78283

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 Ask a Doctor Before Use If 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 8 words ▾

Uses Reduces underarm sweat 24 hour effective protection

⏱️ Dosage and Administration 5 words ▾

Directions Apply to underarms only

⚠️ Warnings 47 words ▾

Warnings For external use only Do not use on broken skin Stop use if rash or irritation occurs Ask a doctor before use if you have kidney disease Keep out of reach of children. If swallowed, get medical help or contact a Posion Control Center right away.

🧪 Active Ingredient 7 words ▾

Active ingredient Aluminum chlorohydrate 20% Purpose Antiperspirant

🧪 Inactive Ingredients 52 words ▾

Inactive ingredients Water (aqua), steareth-2, glycerin, steareth-21, tocopherol acetate octenidine HCL, creosote bush (Larrea tridentata var, tridentata) extract, tocopherol, dimethicone fragrance (parfum), biotin, lecithin, phenoxyethanol, sodium hydroxide, propylene glycol, ethylhexylglycerin, dehydroacetic acid, benzoic acid, sorbic acid, butylene glycol, ascorbic acid, sodium citrate, potassium sorbate, citric acid, sodium metabisulfite, limonene, linalool, hexyl cinnamal.

🎯 Purpose 2 words ▾

Purpose Antiperspirant

📄 Do Not Use 6 words ▾

Do not use on broken skin

📄 Ask a Doctor Before Use If 10 words ▾

Ask a doctor before use if you have kidney disease

📄 Stop Use and Ask a Doctor If 7 words ▾

Stop use if rash or irritation occurs

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Posion Control Center right away.

📄 Package Label / Principal Display Panel 3 words ▾

Package Labeling: Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for ALUMINUM CHLOROHYDRATE — the ingredient across all brands.

Top reported reactions

Expired Product Administered5
Macule5
Product Administered At Inappropriate Site5
Application Site Pain4
Cervix Carcinoma4
Cervix Haemorrhage Uterine4
Erythema4

Reporter sex

40 reports
Male · 32%
Female · 66%
Unknown · 3%

Serious outcomes

Disabling6
Death3
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 17 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Over-the-counter (OTC) product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page it is currently marketed — but BERIOSKA SL has reported a marketing end date of 2030-01-01, after which this package is expected to stop being marketed. The directory data on this page refreshes weekly.
Who lists this product with the FDA?
BERIOSKA SL is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 78283-0002-01 · BERIOSKA 78283-0004-01 · BERIOSKA →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.